Schrodinger (SDGR) Competitors

Schrodinger has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500.

Schrodinger has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

In the previous week, Schrodinger and Schrodinger both had 5 articles in the media. NewAmsterdam Pharma's average media sentiment score of 0.83 beat Schrodinger's score of 0.34 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Schrodinger has a net margin of -40.37% compared to NewAmsterdam Pharma's net margin of -906.22%. NewAmsterdam Pharma's return on equity of -26.67% beat Schrodinger's return on equity.

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 21.0% of Schrodinger shares are held by insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Schrodinger currently has a consensus target price of $20.50, suggesting a potential upside of 59.29%. NewAmsterdam Pharma has a consensus target price of $48.00, suggesting a potential upside of 60.64%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Schrodinger.

Schrodinger has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.

Schrodinger has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

In the previous week, Edgewise Therapeutics had 6 more articles in the media than Schrodinger. MarketBeat recorded 11 mentions for Edgewise Therapeutics and 5 mentions for Schrodinger. Edgewise Therapeutics' average media sentiment score of 0.69 beat Schrodinger's score of 0.34 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Edgewise Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -40.37%. Schrodinger's return on equity of -29.47% beat Edgewise Therapeutics' return on equity.

79.1% of Schrodinger shares are held by institutional investors. 21.0% of Schrodinger shares are held by company insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Schrodinger currently has a consensus target price of $20.50, suggesting a potential upside of 59.29%. Edgewise Therapeutics has a consensus target price of $38.13, suggesting a potential upside of 0.30%. Given Schrodinger's higher possible upside, equities research analysts plainly believe Schrodinger is more favorable than Edgewise Therapeutics.

In the previous week, Schrodinger and Schrodinger both had 5 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 0.76 beat Schrodinger's score of 0.34 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Catalyst Pharmaceuticals has a net margin of 36.39% compared to Schrodinger's net margin of -40.37%. Catalyst Pharmaceuticals' return on equity of 36.47% beat Schrodinger's return on equity.

Schrodinger has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.

Schrodinger currently has a consensus target price of $20.50, suggesting a potential upside of 59.29%. Catalyst Pharmaceuticals has a consensus target price of $34.00, suggesting a potential upside of 10.17%. Given Schrodinger's higher possible upside, equities research analysts plainly believe Schrodinger is more favorable than Catalyst Pharmaceuticals.

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 21.0% of Schrodinger shares are held by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Catalyst Pharmaceuticals has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

In the previous week, Kiniksa Pharmaceuticals International had 32 more articles in the media than Schrodinger. MarketBeat recorded 37 mentions for Kiniksa Pharmaceuticals International and 5 mentions for Schrodinger. Kiniksa Pharmaceuticals International's average media sentiment score of 0.66 beat Schrodinger's score of 0.34 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Schrodinger's net margin of -40.37%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Schrodinger's return on equity.

Kiniksa Pharmaceuticals International has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

Kiniksa Pharmaceuticals International presently has a consensus target price of $60.86, suggesting a potential upside of 7.26%. Schrodinger has a consensus target price of $20.50, suggesting a potential upside of 59.29%. Given Schrodinger's higher probable upside, analysts plainly believe Schrodinger is more favorable than Kiniksa Pharmaceuticals International.

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 21.0% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.